Back to Search
Start Over
Regenerative potential of different extracellular vesicle subpopulations derived from clonal mesenchymal stem cells in a mouse model of chemotherapy-induced premature ovarian failure.
- Source :
-
Life sciences [Life Sci] 2023 May 15; Vol. 321, pp. 121536. Date of Electronic Publication: 2023 Mar 01. - Publication Year :
- 2023
-
Abstract
- Aims: Some studies have shown that mesenchymal stem cells (MSCs) and their derived extracellular vesicles (MSC-EVs) can restore ovarian function in premature ovarian failure (POF), however, concerns about their efficacy are attributed to the heterogeneity of the cell populations and EVs. Here, we assessed the therapeutic potential of a homogeneous population of clonal MSCs (cMSCs) and their EVs subpopulations in a mouse model of POF.<br />Main Methods: Granulosa cells were treated with cyclophosphamide (Cy) in the absence or presence of cMSCs, or cMSCs-derived EV subpopulations (EV20K and EV110K, isolated by high-speed centrifugation and differential ultracentrifugation, respectively). In addition, POF mice were treated with cMSCs, EV20K and/or EV110K.<br />Key Findings: cMSC and both EV types protected granulosa cells from Cy-induced damage. Calcein-EVs were detected in the ovaries. Moreover, cMSC and both EV subpopulations significantly increased body weight, ovary weight, and the number of follicles, restored FSH, E2, and AMH levels, increased the granulosa cell numbers and restored the fertility of POF mice. cMSC, EV20K, and EV110K alleviated inflammatory-related genes expression (Tnf-α and IL8), and improved angiogenesis via upregulation expression of Vegf and Igf1 at the mRNA level and VEGF and αSMA at the protein level. They also inhibited apoptosis through the PI3K/AKT signaling pathway.<br />Significance: The administration of cMSCs and two cMSC-EVs subpopulations improved ovarian function and restored fertility in a POF model. EV20K is more cost-effective and feasible in terms of isolation, particularly in good manufacturing practice (GMP) facilities for treatment of POF patients in comparison with conventional EVs (EV110K).<br />Competing Interests: Declaration of competing interest None declared.<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Subjects :
- Female
Humans
Mice
Animals
Phosphatidylinositol 3-Kinases metabolism
Vascular Endothelial Growth Factor A metabolism
Cyclophosphamide adverse effects
Primary Ovarian Insufficiency chemically induced
Primary Ovarian Insufficiency therapy
Primary Ovarian Insufficiency metabolism
Mesenchymal Stem Cells metabolism
Antineoplastic Agents adverse effects
Extracellular Vesicles metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0631
- Volume :
- 321
- Database :
- MEDLINE
- Journal :
- Life sciences
- Publication Type :
- Academic Journal
- Accession number :
- 36868400
- Full Text :
- https://doi.org/10.1016/j.lfs.2023.121536